Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.180
-0.270 (-7.83%)
At close: Apr 1, 2025, 4:00 PM
3.400
+0.220 (6.92%)
After-hours: Apr 1, 2025, 4:29 PM EDT
Alterity Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Alterity Therapeutics stock has a target of 12, which predicts an increase of 277.36% from the current stock price of 3.18.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 30, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Alterity Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +277.36% | Jan 30, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +151.57% | Dec 12, 2024 |
| Benchmark | Benchmark | Buy Reiterates $4 | Buy | Reiterates | $4 | +25.79% | Mar 7, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $20 → $10 | Strong Buy | Maintains | $20 → $10 | +214.47% | Jun 5, 2023 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +528.93% | Aug 3, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.